---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Co-prescribed/Concomitant therapies. Topics: Positive airway pressure: initiation permitted during the phase 3 trials; Allowed and disallowed concomitant medications in the phase 3 trials; GLP-1 receptor agonists: pooled phase 3 exploratory analysis of weight change, participants taking a GLP-1 receptor agonist for diabetes; GLP-1 receptor agonists: company summary of concomitant use in the phase 3 trials; 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Positive airway pressure: initiation permitted during the phase 3 trials

> “Participants are not prohibited from initiating PAP during the trial if deemed by the participant's primary care provider to be in the participant's best medical interest. Dosing of AD109 or placebo can continue if PAP is initiated.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-2.1.2.12-2"></a>

### Allowed and disallowed concomitant medications in the phase 3 trials

> “Inhaled corticosteroid, and antidiabetics, including those associated with weight loss”
> “Drugs used exclusively for weight loss”
> “Modafinil, armodafinil, solriamfetol, and pitolisant”
> “Benzodiazepines, Z-drugs, DORAs, and trazodone”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-2.1.2.12-3"></a>

### GLP-1 receptor agonists: pooled phase 3 exploratory analysis of weight change, participants taking a GLP-1 receptor agonist for diabetes

> “Participants receiving GLP-1 RA for diabetes were permitted.”
> “One-hundred and six participants were enrolled in the phase 3 trials taking a GLP-1 RA for diabetes (PBO+GLP-1 RA: n=48; AD109+GLP-1 RA: n=58).”
> “In participants receiving a GLP-1 RA with baseline BMI ≥35, AD109 reduced weight by 5.5% (vs PBO: 0.9%, P=0.02) and 11.5% (vs PBO: 3.8%, P=0.04) at Week 26 and Week 51, respectively.”

Source: [Strollo et al. (2026a)](https://academic.oup.com/sleep/article/49/Supplement_1/A261/8673726)

<a id="topic-2.1.2.12-4"></a>

### GLP-1 receptor agonists: company summary of concomitant use in the phase 3 trials

> “A subset of participants in the Phase 3 SynAIRgy and LunAIRo trials were receiving concomitant GLP-1 receptor agonists at stable doses, most commonly semaglutide. Across these trials, the effects of AD109 on AHI reduction were directionally similar in participants receiving GLP-1 therapy and those not receiving GLP-1 therapy, suggesting that the treatment effect of AD109 was additive to GLP-1 use in participants on stable doses.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.12-5"></a>

### GLP-1 receptor agonists for weight loss: SynAIRgy exploratory cohort not analyzed

> “Due to low enrollment in this cohort, the prespecified exploratory analyses are not included in this report.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.1.2.12-6"></a>

### GLP-1 receptor agonists: open-label phase 2 co-administration study

> “Forty participants were enrolled and received AD109 (n=22) or AD109+GLP-1 RA (n=18).”
> “AD109 was generally safe and well-tolerated in both treatment arms of this phase 2 trial, without large differences in PK when co-administered with GLP-1 RA.”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="topic-2.1.2.12-7"></a>

### Intended use alongside PAP or GLP-1 therapy

> “Thereafter, we intend to focus on patients using another treatment who have not fully resolved their OSA, for example, providing Oxnimbi as a compliment to PAP or GLP-1s.”
> “A Wells Fargo survey conducted in August of 2025 reported that 84% of surveyed healthcare providers familiar with Oxnimbi intend to prescribe it, if approved, either as a first-line therapy, after PAP or together with PAP”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
